{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-22-000058","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.036312+00:00","generated_at":"2026-06-21T11:23:02.399537+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integra to acquire SIA for up to $140M; plans $150M share buyback","bullets":["Integra buys SIA for $50M at closing plus up to $90M in milestones; deal expected to close by end of 2022.","SIA 2022E revenue ~$5M; gross margin >75%. Acquisition dilutive ~$0.06 in Year 1, accretive in Year 3.","ROIC expected to exceed 10% by Year 5 (2027).","Plans $150M share repurchase starting early 2023 to largely offset Year 1 dilution.","No FDA-approved surgical matrices for IBBR; Integra's SurgiMend PMA under review, DuraSorb IDE ~70% enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-22-000058","json":"https://secwatch.observer/filing/0000917520-22-000058.json","markdown":"https://secwatch.observer/filing/0000917520-22-000058.md","text":"https://secwatch.observer/filing/0000917520-22-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752022000058/0000917520-22-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752022000058/iart-20221130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:23:02.399537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}